Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Icon ( (ICLR) ) has shared an announcement.
On July 23, 2025, ICON plc reported its financial results for the second quarter ending June 30, 2025. The company achieved gross business wins of $2,966 million, with net business wins of $2,057 million, and reported a revenue of $2,017.4 million, marking a slight increase from the previous quarter. Despite a decrease in revenue compared to the same period in 2024, ICON saw a significant year-over-year increase in net income by 30.7%, reaching $183.0 million. The company also repurchased $250 million worth of stock and expanded its share repurchase program by $500 million. ICON updated its full-year 2025 financial guidance, expecting revenue between $7,850 and $8,150 million and adjusted diluted earnings per share between $13.00 and $14.00, reflecting strong cost management and increased pass-through revenue expectations.
The most recent analyst rating on (ICLR) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score is driven by strong financial performance and moderate valuation. The company’s robust profitability and cash management are significant strengths. However, challenges highlighted in the earnings call, including revenue declines and elevated cancellations, weigh on the outlook. Technical indicators suggest positive short-term momentum but caution due to potential overbought conditions.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a world-leading clinical research organization headquartered in Dublin, Ireland, specializing in providing outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations. The company is powered by healthcare intelligence and focuses on advancing clinical research from molecule to medicine, employing approximately 39,900 people across 95 locations in 55 countries.
Average Trading Volume: 1,521,726
Technical Sentiment Signal: Sell
Current Market Cap: $13.04B
For detailed information about ICLR stock, go to TipRanks’ Stock Analysis page.